Inflammatory and anti-inflammatory markers in acute coronary syndromes. Ready for use in the clinical setting?;Marcadores de inflamación y de antiinflamación en el síndrome coronario agudo: ¿Listos para usarlos en la práctica clínica?

Revista Espanola de Cardiologia

Volumn 58, Issue 6, 2005, Pages 615-617

  García Moll, Xavier ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID A PROTEIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; FIBRINOGEN; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; LYMPHOTOXIN; TROPONIN; TUMOR NECROSIS FACTOR ALPHA;

ATHEROSCLEROSIS; EDITORIAL; HEART MUSCLE ISCHEMIA; HUMAN; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; ST SEGMENT ELEVATION;

EID: 23044494255     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1157/13076412     Document Type: Editorial

References (14)

1. Angiolillo DJ, Biasucci LM, Liuzzo G, Crea F. La inflamación en los síndromes coronarios agudos: mecanismos e implicaciones clínicas. Rev Esp Cardiol. 2004;57:433-46.
2. White PD. Heart Disease. New York: The MacMillan Company; 1949.
3. Cole D, Singian E, Katz L. The long-term prognosis following myocardial infarction, and some factors which affect it. Circulation. 1954;9:321-34.
4. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. J Am Med Assoc. 1998;279:1477-82.
5. García-Moll X, Kaski JC. Cardiopatía isquémica: marcadores de inflamación y riesgo cardiovascular. Rev Esp Cardiol. 1999;52: 990-1003.
6. Coller BS. Leukocytosis and ischemic vascular disease morbidity and mortality. Is it time to intervene? Arterioscler Thromb Vasc Biol. 2005;25:658-70.
7. Núñez J, Fácila L, Llácer A, Sanchís J, Bodí V, Bertomeu V, et al. Valor pronóstico del recuento leucocitario en el infarto agudo de miocardio: mortalidad a largo plazo. Rev Esp Cardiol. 2005; 58:631-9.
8. De Vries JE. Immunosupressive and anti-inflammatory properties of interleukin-10. Ann Med. 1995;27:537-41.
9. Pérez Fernández R, Kaski JC. Interleucina-10 y enfermedad coronaria. Rev Esp Cardiol. 2002;55:738-50.
10. Domínguez Rodríguez A, Abreu González P, García González MJ, Ferrer Hita J. Asociación entre concentraciones séricas de interleucina-10 y desarrollo de insuficiencia cardíaca en pacientes con infarto agudo de miocardio tratados con angioplastia primaria. Rev Esp Cardiol. 2005; 58:626-30.
11. Levinson SS, Elin RJ. What is C-reactive protein telling us about coronary artery disease? Arch Intern Med. 2002;162:389-92.
12. García-Moll X, Ordóñez-Llanos J. Role of hs-CRP measurements in the current cardiovascular risk assessment. Clin Chim Acta. 2005;355:215-8.
13. Campbell B, Badrick T, Flatman R, Kanowski D. Limited clinical utility of high-sensitivity plasma C-reactive protein assays. Ann Clin Biochem. 2002;39:85-8.
14. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, et al. Centers for Disease Control and Prevention, and American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511.